Fibroblast growth factor 23 and 25(OH)D levels are related to abdominal obesity and cardiovascular risk in patients with polycystic ovarian syndrome

Abstract

Fibroblast growth factor 23 (FGF23) and Klotho are extensively studied in relation to bone metabolism and progression of chronic kidney disease. There is very limited information about their role in polycystic ovarian syndrome (PCOS). The aim of the present study was to investigate some bone markers in women with PCOS in relation to obesity and cardiovascular risk. In the study were included 80 patients, divided into three age-matched groups –Non-obese PCOS (n = 40); Obese PCOS (n = 20) and Obese control group (n = 20). Bone marker levels were measured by an enzyme-linked immunosorbent assay. Obese PCOS patients had higher levels of FGF23 and sRANKL, lower levels of 25(OH)D and higher prevalence of vitamin D deficiency compared to non-obese subjects. Patients with abdominal obesity (waist circumference >80 cm) independently of PCOS status had significantly higher levels of FGF23 (112.5 ± 86.5 vs. 73.4 ± 37.9 pg/ml; p = .023) and lower of 25(OH)D (35.8 ± 21.4 vs 47.8 ± 26.5 nmol/l; p = .034). Patients with PCOS at risk of cardiovascular diseases according to AE-PCOS consensus also had increased levels of FGF23 (111.6 ± 84.5 vs. 66.5 ± 35.1 pg/ml; p = .031) and decreased levels of 25(OH)D (31.9 ± 16.8 vs. 47.1 vs 28.4 nmol/l; p = .017) compared to those not at risk. There was no correlation between bone markers and blood glucose levels, insulin resistance or hormonal levels.

摘要

针对成纤维细胞生长因子23（FGF23）和Klotho与骨代谢和慢性肾脏病进展中的关系有广泛研究。关于其在多囊卵巢综合征（PCOS）中的作用信息十分有限。该研究旨在研究一些骨代谢标志物与多囊卵巢综合征患者肥胖与心血管风险的相关性。该研究共纳入80名患者, 将其分为三个年龄相匹配的组：非肥胖PCOS组（n=40）；肥胖PCOS组（n=20）;肥胖对照组（n=20）。酶联免疫吸附法检测骨代谢标志物水平。与非肥胖受试者相比, 肥胖型PCOS患者其FGF23与sRANKL水平更高, 25(OH)D水平更低, 维生素D缺乏患病率更高。腹型肥胖（腰围>80cm）的非PCOS患者FGF23更高(112.5±86.5 vs. 73.4±37.9pg/ml; p＝.023), 25(OH)D水平更低(35.8±21.4 vs 47.8±26.5nmol/l; p＝.034)。根据AE-PCOS共识, 与无心血管疾病风险的PCOS患者相比, 有心血管疾病风险的PCOS患者其FGF23水平更高(111.6±84.5 vs. 66.5±35.1pg/ml; p＝.031), 25(OH)D水平更低(31.9±16.8vs. 47.1±28.4nmol/l; p＝.017)。骨代谢标志物与血糖水平、胰岛素抵抗和激素水平之间没有相关性。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• PCOS
• FGF23
• Klotho
• 25(OH)D

Disclosure statement

The authors declare no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Additional information

Funding

The study was performed with the financial support of Medical University-Sofia, Bulgaria, Grant 2018, Project №7738/22.11.2017, Contract D-103/03.05.2018.